Impact and Implications of Lung Cancer Screening

In this video at ASCO 2018, James Mulshine, MD, discusses CMS coverage of low-dose CT lung cancer screening for selected Medicare beneficiaries, and clinical implications of early detection.

Related Content:

ASCO Annual Meeting: Lung CancerConference

Pembrolizumab and Etoposide Continue to Demonstrate Clinically Meaningful Survival Benefit in Untreated ES-SCLC

Frontline Tremelimumab/Durvalumab Combo Shows Promising Survival Benefit in Hard-to-Treat Subgroups of mNSCLC

Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC